文献速递膀胱癌与上尿路尿路上皮癌

BCG失败模式对高危非肌层浸润性膀胱癌膀胱内吉西他滨/多西他赛疗效的影响

Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2026-02-25

该研究纳入143例高危非肌层浸润性膀胱癌患者,按FDA/IBCG定义将BCG失败分为早期非难治性、早期难治性和晚期复发三型,评估膀胱内吉西他滨/多西他赛的疗效。结果显示晚期复发者12个月无复发生存率最高(84%),早期难治性最低(54%),且早期失败类型与复发风险显著升高相关。

要点

  • BCG失败分型影响吉西他滨/多西他赛疗效,晚期复发者预后最佳。
  • 早期难治性BCG失败者12个月无复发生存率仅54%,疾病控制最差。
  • 多变量分析显示早期失败类型与复发风险显著升高独立相关。

核心结论

  • 吉西他滨/多西他赛对各类BCG失败均显示有意义的活性,但晚期复发者结局最好,难治性疾病控制最差。

研究设计与样本

  • 回顾性队列研究,纳入143例高危非肌层浸润性膀胱癌患者,按FDA/IBCG定义分类BCG失败模式。

主要发现

  • 12个月无复发生存率:早期非难治性67%(95%CI 55-82%),早期难治性54%(95%CI 36-82%),晚期复发84%(95%CI 70-100%),P<0.05。
  • 12个月高级别无复发生存率:早期非难治性75%(95%CI 64-88%),早期难治性58%(95%CI 39-87%),晚期复发87%(95%CI 75-100%),P<0.05。
  • 12个月无进展生存率在所有组均>90%。
  • 多变量分析:早期非难治性BCG失败aHR 3.20(95%CI 1.31-7.82,P=0.011),早期难治性aHR 3.59(95%CI 1.28-10.1,P=0.015),均与复发风险显著升高相关(相比晚期复发)。

临床怎么用

  • 选择BCG失败后膀胱内吉西他滨/多西他赛治疗候选者时,应区分BCG失败亚型。
  • 晚期BCG复发患者可能从吉西他滨/多西他赛中获得更优获益。

局限性

  • 中位随访仅12个月,长期肿瘤学结局未明。
  • 回顾性设计可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the impact of specific Bacillus Calmette-Guérin (BCG) failure phenotypes on treatment outcomes with intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer (HR-NMIBC). PATIENTS AND METHODS: A BCG failure was classified according to the United States Food and Drug Administration (FDA)/International Bladder Cancer Group (IBCG) definitions and analysed as early refractory BCG failure, early non-refractory BCG failure, or late BCG relapse. Kaplan-Meier methods were used to estimate recurrence-free survival (RFS), high-grade RFS (HG-RFS), and progression-free survival (PFS). Multivariable Cox proportional hazards models, adjusted for histology, multifocality, and tumour size, were used to assess the association between BCG failure patterns and oncological outcomes. RESULTS: Among the 143 patients included, 72 had early non-refractory BCG failure, 36 had early refractory BCG failure, and 35 experienced late BCG relapse. The median follow-up was 12 months. At 12 months, the RFS was 67% (95% confidence interval [CI] 55-82%) in early non-refractory BCG failure, 54% (95% CI 36-82%) in early refractory BCG failure, and 84% (95% CI 70-100%) in late BCG relapse (P < 0.05). Corresponding HG-RFS rates were 75% (95% CI 64-88%), 58% (95% CI 39-87%), and 87% (95% CI 75-100%), respectively (P < 0.05). The PFS remained >90% across all groups at 12 months. On multivariable analysis, both early non-refractory BCG failure (adjusted hazard ratio [aHR] 3.20, 95% CI 1.31-7.82; P = 0.011) and early refractory BCG failure (aHR 3.59, 95% CI 1.28-10.1; P = 0.015) were associated with a significantly higher risk of recurrence compared with late BCG relapse, with consistent findings for HG recurrence. CONCLUSIONS: Gemcitabine/docetaxel demonstrated meaningful activity across all BCG failure types, with late BCG relapsing patients achieving the most favourable outcomes and refractory disease showing the poorest control. These findings underscore the clinical relevance of distinguishing BCG failure subtypes when selecting candidates for post-BCG intravesical gemcitabine/docetaxel and designing future prospective trials.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Scilipoti P, Zaurito P, Longoni M, et al. Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer. BJU Int. 2026. PMID: 41742675. doi:10.1111/bju.70182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。